Abstract
Glioblastoma (GBM) is an aggressive and lethal disease that often results in a poor prognosis. Unlike most solid tumors, GBM is characterized by diffuse infiltrating margins, extensive angiogenesis, hypoxia, necrosis, and clonal heterogeneity. Recurrent disease is an unavoidable consequence for many patients as standard treatment options such as surgery, radiotherapy, and chemotherapy have proven to be insufficient in causing long-term survival benefits. Systemic delivery of promising drugs is hindered due to the blood–brain barrier and non-uniform perfusion within GBM tissue. In recent years, many investigations have highlighted the role of GBM stem cells (GSCs) and their microenvironment in the initiation and maintenance of tumor tissue. Preclinical and early clinical studies to target GSCs and microenvironmental components are currently underway. Of these strategies, immunotherapy using checkpoint inhibitors and redirected cytotoxic T cells have shown promising results in early investigations. But, GBM microenvironment is heterogenous and recent investigations have shown cell populations within this microenvironment to be plastic. These studies underline the importance of identifying the role of and targeting multiple cell populations within the GBM microenvironment which could have a synergistic effect when combined with novel therapies. Pericytes are multipotent perivascular cells that play a vital role within the GBM microenvironment by assisting in tumor initiation, survival, and progression. Due to their role in regulating the blood–brain barrier permeability, promoting angiogenesis, tumor growth, clearing extracellular matrix for infiltrating GBM cells and in helping GBM cells evade immune surveillance, pericytes could be ideal therapeutic targets for stymieing or exploiting their role within the GBM microenvironment. This chapter will introduce hallmarks of GBM and elaborate on the contributions of pericytes to these hallmarks by examining recent findings. In addition, the chapter also highlights the therapeutic value of targeting pericytes, while discussing conventional and novel GBM therapies and obstacles to their efficacy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abbott, N. J. (2002). Astrocyte-endothelial interactions and blood-brain barrier permeability. Journal of Anatomy, 200(6), 629–638.
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010). Structure and function of the blood–brain barrier. Neurobiology of Disease, 37(1), 13–25. https://doi.org/10.1016/j.nbd.2009.07.030.
Abramsson, A., Berlin, Ö., Papayan, H., Paulin, D., Shani, M., & Betsholtz, C. (2002). Analysis of mural cell recruitment to tumor vessels. Circulation, 105(1), 112.
Agarwal, S., Manchanda, P., Vogelbaum, M. A., Ohlfest, J. R., & Elmquist, W. F. (2013). Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: Findings in an orthotopic rat xenograft model of glioma. Drug Metabolism and Disposition, 41(1), 33–39. https://doi.org/10.1124/dmd.112.048322.
Alcantara Llaguno, S. R., Wang, Z., Sun, D., Chen, J., Xu, J., Kim, E., et al. (2015). Adult lineage restricted CNS progenitors specify distinct glioblastoma subtypes. Cancer Cell, 28(4), 429–440. https://doi.org/10.1016/j.ccell.2015.09.007.
Alsaab, H. O., Sau, S., Alzhrani, R., Tatiparti, K., Bhise, K., Kashaw, S. K., & Iyer, A. K. (2017). PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Frontiers in Pharmacology, 8, 561. https://doi.org/10.3389/fphar.2017.00561.
Appaix, F., Nissou, M. F., van der Sanden, B., Dreyfus, M., Berger, F., Issartel, J. P., & Wion, D. (2014). Brain mesenchymal stem cells: The other stem cells of the brain? World Journal of Stem Cells, 6(2), 134–143. https://doi.org/10.4252/wjsc.v6.i2.134.
Armulik, A., Genové, G., & Betsholtz, C. (2011). Pericytes: Developmental, physiological, and pathological perspectives, problems, and promises. Developmental Cell, 21(2), 193–215. https://doi.org/10.1016/j.devcel.2011.07.001.
Assanah, M., Lochhead, R., Ogden, A., Bruce, J., Goldman, J., & Canoll, P. (2006). Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. The Journal of Neuroscience, 26(25), 6781.
Augustin, H. G., & Reiss, Y. (2003). EphB receptors and ephrinB ligands: Regulators of vascular assembly and homeostasis. Cell and Tissue Research, 314(1), 25–31. https://doi.org/10.1007/s00441-003-0770-9.
Balabanov, R., Washington, R., Wagnerova, J., & Dore-Duffy, P. (1996). CNS microvascular pericytes express macrophage-like function, cell surface integrin alpha M, and macrophage marker ED-2. Microvascular Research, 52(2), 127–142. https://doi.org/10.1006/mvre.1996.0049.
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., et al. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444(7120), 756–760. https://doi.org/10.1038/nature05236.
Baskar, R., Lee, K. A., Yeo, R., & Yeoh, K.-W. (2012). Cancer and radiation therapy: Current advances and future directions. International Journal of Medical Sciences, 9(3), 193–199. https://doi.org/10.7150/ijms.3635.
Behling, K., Maguire, W. F., Di Gialleonardo, V., Heeb, L. E. M., Hassan, I. F., Veach, D. R., et al. (2016). Remodeling the vascular microenvironment of glioblastoma with α-particles. Journal of Nuclear Medicine, 57(11), 1771–1777. https://doi.org/10.2967/jnumed.116.173559.
Bell, R. D., Winkler, E. A., Sagare, A. P., Singh, I., LaRue, B., Deane, R., & Zlokovic, B. V. (2010). Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron, 68(3), 409–427. https://doi.org/10.1016/j.neuron.2010.09.043.
Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., et al. (2012). Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature, 485(7399), 512–516. https://doi.org/10.1038/nature11087.
Ben-Zvi, A., Lacoste, B., Kur, E., Andreone, B. J., Mayshar, Y., Yan, H., & Gu, C. (2014). Mfsd2a is critical for the formation and function of the blood–brain barrier. Nature, 509, 507. https://doi.org/10.1038/nature13324. https://www.nature.com/articles/nature13324#supplementary-information.
Bentolila, L. A., Prakash, R., Mihic-Probst, D., Wadehra, M., Kleinman, H. K., Carmichael, T. S., et al. (2016). Imaging of angiotropism/vascular co-option in a murine model of brain melanoma: Implications for melanoma progression along extravascular pathways. Scientific Reports, 6, 23834. https://doi.org/10.1038/srep23834. https://www.nature.com/articles/srep23834#supplementary-information.
Bergers, G., & Hanahan, D. (2008). Modes of resistance to anti-angiogenic therapy. Nature Reviews Cancer, 8(8), 592–603. https://doi.org/10.1038/nrc2442.
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003). Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. The Journal of Clinical Investigation, 111(9), 1287–1295. https://doi.org/10.1172/jci17929.
Birbrair, A., Borges, I. D. T., Gilson Sena, I. F., Almeida, G. G., da Silva Meirelles, L., Goncalves, R., et al. (2017a). How plastic are pericytes? Stem Cells and Development, 26(14), 1013–1019. https://doi.org/10.1089/scd.2017.0044.
Birbrair, A., & Frenette, P. S. (2016). Niche heterogeneity in the bone marrow. Annals of the New York Academy of Sciences, 1370(1), 82–96. https://doi.org/10.1111/nyas.13016.
Birbrair, A., Sattiraju, A., Zhu, D., Zulato, G., Batista, I., Nguyen, V. T., et al. (2017b). Novel peripherally derived neural-like stem cells as therapeutic carriers for treating glioblastomas. Stem Cells Translational Medicine, 6(2), 471–481. https://doi.org/10.5966/sctm.2016-0007.
Birbrair, A., Wang, Z.-M., Messi, M. L., Enikolopov, G. N., & Delbono, O. (2011). Nestin-GFP transgene reveals neural precursor cells in adult skeletal muscle. PLoS One, 6(2), e16816. https://doi.org/10.1371/journal.pone.0016816.
Birbrair, A., Zhang, T., Wang, Z.-M., Messi, M. L., Enikolopov, G. N., Mintz, A., & Delbono, O. (2013a). Skeletal muscle neural progenitor cells exhibit properties of NG2-glia. Experimental Cell Research, 319(1), 45–63. https://doi.org/10.1016/j.yexcr.2012.09.008.
Birbrair, A., Zhang, T., Wang, Z.-M., Messi, M. L., Mintz, A., & Delbono, O. (2013b). Type-1 pericytes participate in fibrous tissue deposition in aged skeletal muscle. American Journal of Physiology-Cell Physiology, 305(11), C1098–C1113. https://doi.org/10.1152/ajpcell.00171.2013.
Birbrair, A., Zhang, T., Wang, Z.-M., Messi, M. L., Mintz, A., & Delbono, O. (2014a). Pericytes: Multitasking cells in the regeneration of injured, diseased, and aged skeletal muscle. Frontiers in Aging Neuroscience, 6, 245. https://doi.org/10.3389/fnagi.2014.00245.
Birbrair, A., Zhang, T., Wang, Z.-M., Messi, M. L., Olson, J. D., Mintz, A., & Delbono, O. (2014b). Type-2 pericytes participate in normal and tumoral angiogenesis. American Journal of Physiology-Cell Physiology, 307(1), C25–C38. https://doi.org/10.1152/ajpcell.00084.2014.
Birbrair, A., Zhang, T., Wang, Z. M., Messi, M. L., Mintz, A., & Delbono, O. (2015). Pericytes at the intersection between tissue regeneration and pathology. Clinical Science (London, England), 128(2), 81–93. https://doi.org/10.1042/cs20140278.
Bissell, M. J., & Radisky, D. (2001). Putting tumours in context. Nature Reviews Cancer, 1(1), 46–54. https://doi.org/10.1038/35094059.
Bobo, R. H., Laske, D. W., Akbasak, A., Morrison, P. F., Dedrick, R. L., & Oldfield, E. H. (1994). Convection-enhanced delivery of macromolecules in the brain. Proceedings of the National Academy of Sciences, 91(6), 2076–2080.
Bose, A., Barik, S., Banerjee, S., Ghosh, T., Mallick, A., Bhattacharyya Majumdar, S., et al. (2013). Tumor-derived vascular pericytes anergize Th cells. The Journal of Immunology, 191, 971–981.
Bradshaw, A., Wickremsekera, A., Tan, S. T., Peng, L., Davis, P. F., & Itinteang, T. (2016). Cancer stem cell hierarchy in glioblastoma multiforme. Frontiers in Surgery, 3, 21. https://doi.org/10.3389/fsurg.2016.00021.
Brady, J., Neal, J., Sadakar, N., & Gasque, P. (2004). Human endosialin (tumor endothelial marker 1) is abundantly expressed in highly malignant and invasive brain tumors. Journal of Neuropathology and Experimental Neurology, 63(12), 1274–1283.
Brat, D. J., Castellano-Sanchez, A. A., Hunter, S. B., Pecot, M., Cohen, C., Hammond, E. H., et al. (2004). Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Research, 64(3), 920–927. https://doi.org/10.1158/0008-5472.can-03-2073.
Brat, D. J., & Van Meir, E. G. (2004). Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Laboratory Investigation, 84, 397. https://doi.org/10.1038/labinvest.3700070.
Brooks, M. D., Sengupta, R., Snyder, S. C., & Rubin, J. B. (2013). Hitting them where they live: Targeting the glioblastoma perivascular stem cell niche. Current Pathobiology Reports, 1(2), 101–110. https://doi.org/10.1007/s40139-013-0012-0.
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., et al. (2016). Regression of glioblastoma after chimeric antigen receptor T-cell therapy. The New England Journal of Medicine, 375(26), 2561–2569. https://doi.org/10.1056/NEJMoa1610497.
Bruna, A., Darken, R. S., Rojo, F., Ocana, A., Penuelas, S., Arias, A., et al. (2007). High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell, 11(2), 147–160. https://doi.org/10.1016/j.ccr.2006.11.023.
Cabrera, M. C., Hollingsworth, R. E., & Hurt, E. M. (2015). Cancer stem cell plasticity and tumor hierarchy. World Journal of Stem Cells, 7(1), 27–36. https://doi.org/10.4252/wjsc.v7.i1.27.
Calabrese, C., Poppleton, H., Kocak, M., Hogg, T. L., Fuller, C., Hamner, B., et al. (2007). A perivascular niche for brain tumor stem cells. Cancer Cell, 11(1), 69–82. https://doi.org/10.1016/j.ccr.2006.11.020.
Caspani, E. M., Crossley, P. H., Redondo-Garcia, C., & Martinez, S. (2014). Glioblastoma: A pathogenic crosstalk between tumor cells and pericytes. PLoS One, 9(7), e101402. https://doi.org/10.1371/journal.pone.0101402.
Chaffer, C. L., Marjanovic, N. D., Lee, T., Bell, G., Kleer, C. G., Reinhardt, F., et al. (2013). Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell, 154(1), 61–74. https://doi.org/10.1016/j.cell.2013.06.005.
Chaichana, K. L. (2014). The need to continually redefine the goals of surgery for glioblastoma. Neuro-Oncology, 16, 611–612. https://doi.org/10.1093/neuonc/not326.
Chen, J., Ding, Z., Peng, Y., Pan, F., Li, J., Zou, L., et al. (2014). HIF-1α inhibition reverses multidrug resistance in colon cancer cells via downregulation of MDR1/P-glycoprotein. PLoS One, 9(6), e98882. https://doi.org/10.1371/journal.pone.0098882.
Chen, J., Li, Y., Yu, T. S., McKay, R. M., Burns, D. K., Kernie, S. G., & Parada, L. F. (2012). A restricted cell population propagates glioblastoma growth after chemotherapy. Nature, 488(7412), 522–526. https://doi.org/10.1038/nature11287.
Cheng, L., Huang, Z., Zhou, W., Wu, Q., Donnola, S., Liu, J. K., et al. (2013). Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell, 153(1), 139–152. https://doi.org/10.1016/j.cell.2013.02.021.
Chou, C.-W., Wang, C.-C., Wu, C.-P., Lin, Y.-J., Lee, Y.-C., Cheng, Y.-W., & Hsieh, C.-H. (2012). Tumor cycling hypoxia induces chemoresistance in glioblastoma multiforme by upregulating the expression and function of ABCB1. Neuro-Oncology, 14(10), 1227–1238. https://doi.org/10.1093/neuonc/nos195.
Cooke, V. G., LeBleu, V. S., Keskin, D., Khan, Z., O’Connell, J. T., Teng, Y., et al. (2012). Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell, 21(1), 66–81. https://doi.org/10.1016/j.ccr.2011.11.024.
Crisan, M., Yap, S., Casteilla, L., Chen, C. W., Corselli, M., Park, T. S., et al. (2008). A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell, 3(3), 301–313. https://doi.org/10.1016/j.stem.2008.07.003.
Dalerba, P., Cho, R. W., & Clarke, M. F. (2007). Cancer stem cells: Models and concepts. Annual Review of Medicine, 58, 267–284. https://doi.org/10.1146/annurev.med.58.062105.204854.
Daneman, R., Zhou, L., Kebede, A. A., & Barres, B. A. (2010). Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature, 468(7323), 562–566. https://doi.org/10.1038/nature09513.
Das, S., & Marsden, P. A. (2013). Angiogenesis in Glioblastoma. New England Journal of Medicine, 369(16), 1561–1563. https://doi.org/10.1056/NEJMcibr1309402.
Dewhirst, M. W., Cao, Y., & Moeller, B. (2008). Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nature Reviews Cancer, 8(6), 425–437. http://www.nature.com/nrc/journal/v8/n6/suppinfo/nrc2397_S1.html.
Dore-Duffy, P., Owen, C., Balabanov, R., Murphy, S., Beaumont, T., & Rafols, J. A. (2000). Pericyte migration from the vascular wall in response to traumatic brain injury. Microvascular Research, 60(1), 55–69. https://doi.org/10.1006/mvre.2000.2244.
Driessens, G., Kline, J., & Gajewski, T. F. (2009). Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunological Reviews, 229(1), 126–144. https://doi.org/10.1111/j.1600-065X.2009.00771.x.
Dubois, L. G., Campanati, L., Righy, C., D’Andrea-Meira, I., Spohr, T. C. L. d. S. e., Porto-Carreiro, I., et al. (2014). Gliomas and the vascular fragility of the blood brain barrier. Frontiers in Cellular Neuroscience, 8, 418. https://doi.org/10.3389/fncel.2014.00418.
El Hallani, S., Boisselier, B., Peglion, F., Rousseau, A., Colin, C., Idbaih, A., et al. (2010). A new alternative mechanism in glioblastoma vascularization: Tubular vasculogenic mimicry. Brain, 133(Pt 4), 973–982. https://doi.org/10.1093/brain/awq044.
ElAli, A., Thériault, P., & Rivest, S. (2014). The role of pericytes in neurovascular unit remodeling in brain disorders. International Journal of Molecular Sciences, 15(4), 6453–6474. https://doi.org/10.3390/ijms15046453.
Evans, S. M., Judy, K. D., Dunphy, I., Jenkins, W. T., Nelson, P. T., Collins, R., et al. (2004). Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Research, 64(5), 1886–1892.
Eyupoglu, I. Y., Buchfelder, M., & Savaskan, N. E. (2013). Surgical resection of malignant gliomas-role in optimizing patient outcome. Nature Reviews Neurology, 9(3), 141–151.
Fan, X., Khaki, L., Zhu, T. S., Soules, M. E., Talsma, C. E., Gul, N., et al. (2010). NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells, 28(1), 5–16. https://doi.org/10.1002/stem.254.
Fidoamore, A., Cristiano, L., Antonosante, A., d’Angelo, M., Di Giacomo, E., Astarita, C., et al. (2016). Glioblastoma stem cells microenvironment: The paracrine roles of the niche in drug and radioresistance. Stem Cells International, 2016, 6809105. https://doi.org/10.1155/2016/6809105.
Franco, M., Roswall, P., Cortez, E., Hanahan, D., & Pietras, K. (2011). Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood, 118(10), 2906–2917. https://doi.org/10.1182/blood-2011-01-331694.
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., et al. (2009). Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. Journal of Clinical Oncology, 27(28), 4733–4740. https://doi.org/10.1200/jco.2008.19.8721.
Friedmann-Morvinski, D., & Verma, I. M. (2014). Dedifferentiation and reprogramming: Origins of cancer stem cells. EMBO Reports, 15(3), 244–253. https://doi.org/10.1002/embr.201338254.
Furuhashi, M., Sjoblom, T., Abramsson, A., Ellingsen, J., Micke, P., Li, H., et al. (2004). Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Research, 64(8), 2725–2733.
Gerhardt, H., Golding, M., Fruttiger, M., Ruhrberg, C., Lundkvist, A., Abramsson, A., et al. (2003). VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. The Journal of Cell Biology, 161(6), 1163–1177. https://doi.org/10.1083/jcb.200302047.
Gerhardt, H., Wolburg, H., & Redies, C. (2000). N-cadherin mediates pericytic-endothelial interaction during brain angiogenesis in the chicken. Developmental Dynamics, 218(3), 472–479. https://doi.org/10.1002/1097-0177(200007)218:3<472::aid-dvdy1008>3.0.co;2-#.
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., et al. (2014). A randomized trial of bevacizumab for newly diagnosed glioblastoma. New England Journal of Medicine, 370(8), 699–708. https://doi.org/10.1056/NEJMoa1308573.
Gilbertson, R. J., & Rich, J. N. (2007). Making a tumour’s bed: Glioblastoma stem cells and the vascular niche. Nature Reviews Cancer, 7(10), 733–736. https://doi.org/10.1038/nrc2246.
Goldberg, J. S., & Hirschi, K. K. (2009). Diverse roles of the vasculature within the neural stem cell niche. Regenerative Medicine, 4(6), 879–897. https://doi.org/10.2217/rme.09.61.
Goumans, M. J., & Mummery, C. (2000). Functional analysis of the TGFbeta receptor/Smad pathway through gene ablation in mice. The International Journal of Developmental Biology, 44(3), 253–265.
Guichet, P. O., Guelfi, S., Teigell, M., Hoppe, L., Bakalara, N., Bauchet, L., et al. (2015). Notch1 stimulation induces a vascularization switch with pericyte-like cell differentiation of glioblastoma stem cells. Stem Cells, 33(1), 21–34. https://doi.org/10.1002/stem.1767.
Hamanishi, J., Mandai, M., Matsumura, N., Abiko, K., Baba, T., & Konishi, I. (2016). PD-1/PD-L1 blockade in cancer treatment: Perspectives and issues. International Journal of Clinical Oncology, 21(3), 462–473. https://doi.org/10.1007/s10147-016-0959-z.
Hamza, M. A., Mandel, J. J., Conrad, C. A., Gilbert, M. R., Yung, W. K., Puduvalli, V. K., & DeGroot, J. F. (2014). Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. Journal of Neuro-Oncology, 119(1), 135–140. https://doi.org/10.1007/s11060-014-1460-z.
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013.
Hawkes, C. A., Hartig, W., Kacza, J., Schliebs, R., Weller, R. O., Nicoll, J. A., & Carare, R. O. (2011). Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathologica, 121(4), 431–443. https://doi.org/10.1007/s00401-011-0801-7.
Heddleston, J. M., Hitomi, M., Venere, M., Flavahan, W. A., Yang, K., Kim, Y., et al. (2011). Glioma stem cell maintenance: The role of the microenvironment. Current Pharmaceutical Design, 17(23), 2386–2401.
Heddleston, J. M., Li, Z., Hjelmeland, A. B., & Rich, J. N. (2009). The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle, 8(20), 3274–3284.
Hellstrom, M., Gerhardt, H., Kalen, M., Li, X., Eriksson, U., Wolburg, H., & Betsholtz, C. (2001). Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. The Journal of Cell Biology, 153(3), 543–553.
Hellstrom, M., Kalen, M., Lindahl, P., Abramsson, A., & Betsholtz, C. (1999). Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development, 126(14), 3047–3055.
Hodges, T. R., Ferguson, S. D., & Heimberger, A. B. (2016). Immunotherapy in glioblastoma: Emerging options in precision medicine. CNS Oncology, 5(3), 175–186. https://doi.org/10.2217/cns-2016-0009.
Huang, F. J., You, W. K., Bonaldo, P., Seyfried, T. N., Pasquale, E. B., & Stallcup, W. B. (2010). Pericyte deficiencies lead to aberrant tumor vascularizaton in the brain of the NG2 null mouse. Developmental Biology, 344(2), 1035–1046. https://doi.org/10.1016/j.ydbio.2010.06.023.
Huang, P., Rani, M. R., Ahluwalia, M. S., Bae, E., Prayson, R. A., Weil, R. J., et al. (2012). Endothelial expression of TNF receptor-1 generates a proapoptotic signal inhibited by integrin alpha6beta1 in glioblastoma. Cancer Research, 72(6), 1428–1437. https://doi.org/10.1158/0008-5472.can-11-2621.
Iwai, Y., Hamanishi, J., Chamoto, K., & Honjo, T. (2017). Cancer immunotherapies targeting the PD-1 signaling pathway. Journal of Biomedical Science, 24(1), 26. https://doi.org/10.1186/s12929-017-0329-9.
Jackson, M., Hassiotou, F., & Nowak, A. (2015). Glioblastoma stem-like cells: At the root of tumor recurrence and a therapeutic target. Carcinogenesis, 36(2), 177–185. https://doi.org/10.1093/carcin/bgu243.
Jackson, S., ElAli, A., Virgintino, D., & Gilbert, M. R. (2017). Blood-brain barrier pericyte importance in malignant gliomas: What we can learn from stroke and Alzheimer’s disease. Neuro-Oncology, 19(9), 1173–1182. https://doi.org/10.1093/neuonc/nox058.
Jain, R. K., di Tomaso, E., Duda, D. G., Loeffler, J. S., Sorensen, A. G., & Batchelor, T. T. (2007). Angiogenesis in brain tumours. Nature Reviews Neuroscience, 8(8), 610–622. http://www.nature.com/nrn/journal/v8/n8/suppinfo/nrn2175_S1.html.
Jhaveri, N., Chen, T. C., & Hofman, F. M. (2016). Tumor vasculature and glioma stem cells: Contributions to glioma progression. Cancer Letters, 380(2), 545–551. https://doi.org/10.1016/j.canlet.2014.12.028.
Kang, J., Demaria, S., & Formenti, S. (2016). Current clinical trials testing the combination of immunotherapy with radiotherapy. Journal for Immunotherapy of Cancer, 4, 51. https://doi.org/10.1186/s40425-016-0156-7.
Lathia, J. D., Gallagher, J., Heddleston, J. M., Wang, J., Eyler, C. E., Macswords, J., et al. (2010). Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell, 6(5), 421–432. https://doi.org/10.1016/j.stem.2010.02.018.
Lathia, J. D., Mack, S. C., Mulkearns-Hubert, E. E., Valentim, C. L. L., & Rich, J. N. (2015). Cancer stem cells in glioblastoma. Genes & Development, 29(12), 1203–1217. https://doi.org/10.1101/gad.261982.115.
Li, F., Lan, Y., Wang, Y., Wang, J., Yang, G., Meng, F., et al. (2011). Endothelial Smad4 maintains cerebrovascular integrity by activating N-cadherin through cooperation with Notch. Developmental Cell, 20(3), 291–302. https://doi.org/10.1016/j.devcel.2011.01.011.
Liebelt, B. D., Shingu, T., Zhou, X., Ren, J., Shin, S. A., & Hu, J. (2016). Glioma stem cells: Signaling, microenvironment, and therapy. Stem Cells International, 2016, 7849890. https://doi.org/10.1155/2016/7849890.
Liebner, S., & Plate, K. H. (2010). Differentiation of the brain vasculature: The answer came blowing by the Wnt. Journal of Angiogenesis Research, 2(1), 1. https://doi.org/10.1186/2040-2384-2-1.
Lovick, T. A., Brown, L. A., & Key, B. J. (1999). Neurovascular relationships in hippocampal slices: Physiological and anatomical studies of mechanisms underlying flow-metabolism coupling in intraparenchymal microvessels. Neuroscience, 92(1), 47–60.
Lugassy, C., Zadran, S., Bentolila, L. A., Wadehra, M., Prakash, R., Carmichael, S. T., et al. (2014). Angiotropism, pericytic mimicry and extravascular migratory metastasis in melanoma: An alternative to intravascular cancer dissemination. Cancer Microenvironment, 7(3), 139–152. https://doi.org/10.1007/s12307-014-0156-4.
Lyon, J. G., Mokarram, N., Saxena, T., Carroll, S. L., & Bellamkonda, R. V. (2017). Engineering challenges for brain tumor immunotherapy. Advanced Drug Delivery Reviews, 114, 19–32. https://doi.org/10.1016/j.addr.2017.06.006.
Maddaluno, L., Rudini, N., Cuttano, R., Bravi, L., Giampietro, C., Corada, M., et al. (2013). EndMT contributes to the onset and progression of cerebral cavernous malformations. Nature, 498(7455), 492–496. https://doi.org/10.1038/nature12207.
Mancuso, M. R., Davis, R., Norberg, S. M., O’Brien, S., Sennino, B., Nakahara, T., et al. (2006). Rapid vascular regrowth in tumors after reversal of VEGF inhibition. The Journal of Clinical Investigation, 116(10), 2610–2621. https://doi.org/10.1172/jci24612.
Mannino, M., & Chalmers, A. J. (2011). Radioresistance of glioma stem cells: Intrinsic characteristic or property of the ‘microenvironment-stem cell unit’? Molecular Oncology, 5(4), 374–386. https://doi.org/10.1016/j.molonc.2011.05.001.
Martínez-González, A., Calvo, G. F., Pérez Romasanta, L. A., & Pérez-García, V. M. (2012). Hypoxic cell waves around necrotic cores in glioblastoma: A biomathematical model and its therapeutic implications. Bulletin of Mathematical Biology, 74(12), 2875–2896. https://doi.org/10.1007/s11538-012-9786-1.
McCord, A. M., Jamal, M., Shankavaram, U. T., Lang, F. F., Camphausen, K., & Tofilon, P. J. (2009). Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Molecular Cancer Research, 7(4), 489–497. https://doi.org/10.1158/1541-7786.mcr-08-0360.
Mendez, O., Zavadil, J., Esencay, M., Lukyanov, Y., Santovasi, D., Wang, S. C., et al. (2010). Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Molecular Cancer, 9, 133. https://doi.org/10.1186/1476-4598-9-133.
Murat, A., Migliavacca, E., Gorlia, T., Lambiv, W. L., Shay, T., Hamou, M. F., et al. (2008). Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. Journal of Clinical Oncology, 26(18), 3015–3024. https://doi.org/10.1200/jco.2007.15.7164.
Nakada, M., Nambu, E., Furuyama, N., Yoshida, Y., Takino, T., Hayashi, Y., et al. (2013). Integrin α3 is overexpressed in glioma stem-like cells and promotes invasion. British Journal of Cancer, 108(12), 2516–2524. https://doi.org/10.1038/bjc.2013.218.
Nduom, E. K., Weller, M., & Heimberger, A. B. (2015). Immunosuppressive mechanisms in glioblastoma. Neuro-Oncology, 17(suppl_7), vii9–vii14. https://doi.org/10.1093/neuonc/nov151.
Niklasson, M., Jarvius, M., Haglund, C., Chantzi, E., Bergström, T., Nyberg, F., et al. (2017). Abstract 4175: Targeting of a mesenchymal profile in order to sensitize multitherapy resistant glioblastoma clones. Cancer Research, 77(13 Supplement), 4175.
Ochs, K., Sahm, F., Opitz, C. A., Lanz, T. V., Oezen, I., Couraud, P. O., et al. (2013). Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma. Journal of Neuroimmunology, 265(1-2), 106–116. https://doi.org/10.1016/j.jneuroim.2013.09.011.
Ogden, A. T., Waziri, A. E., Lochhead, R. A., Fusco, D., Lopez, K., Ellis, J. A., et al. (2008). Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. Neurosurgery, 62(2), 505–514.; discussion 514–505. https://doi.org/10.1227/01.neu.0000316019.28421.95.
Pardridge, W. M. (2005). The blood-brain barrier: Bottleneck in brain drug development. NeuroRx, 2(1), 3–14.
Pardridge, W. M. (2012). Drug transport across the blood–brain barrier. Journal of Cerebral Blood Flow & Metabolism, 32(11), 1959–1972. https://doi.org/10.1038/jcbfm.2012.126.
Persano, L., Pistollato, F., Rampazzo, E., Della Puppa, A., Abbadi, S., Frasson, C., et al. (2012). BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression. Cell Death & Disease, 3, e412. http://www.nature.com/cddis/journal/v3/n10/suppinfo/cddis2012153s1.html.
Persidsky, Y., Ramirez, S. H., Haorah, J., & Kanmogne, G. D. (2006). Blood–brain barrier: Structural components and function under physiologic and pathologic conditions. Journal of Neuroimmune Pharmacology, 1(3), 223–236. https://doi.org/10.1007/s11481-006-9025-3.
Pieper, C., Marek, J. J., Unterberg, M., Schwerdtle, T., & Galla, H. J. (2014). Brain capillary pericytes contribute to the immune defense in response to cytokines or LPS in vitro. Brain Research, 1550, 1–8. https://doi.org/10.1016/j.brainres.2014.01.004.
Pieper, C., Pieloch, P., & Galla, H. J. (2013). Pericytes support neutrophil transmigration via interleukin-8 across a porcine co-culture model of the blood-brain barrier. Brain Research, 1524, 1–11. https://doi.org/10.1016/j.brainres.2013.05.047.
Razavi, S.-M., Lee, K. E., Jin, B. E., Aujla, P. S., Gholamin, S., & Li, G. (2016). Immune evasion strategies of glioblastoma. Frontiers in Surgery, 3, 11. https://doi.org/10.3389/fsurg.2016.00011.
Reis, M., & Liebner, S. (2013). Wnt signaling in the vasculature. Experimental Cell Research, 319(9), 1317–1323. https://doi.org/10.1016/j.yexcr.2012.12.023.
Reiss, Y., Machein, M. R., & Plate, K. H. (2005). The role of angiopoietins during angiogenesis in gliomas. Brain Pathology, 15(4), 311–317. https://doi.org/10.1111/j.1750-3639.2005.tb00116.x.
Reyahi, A., Nik, A. M., Ghiami, M., Gritli-Linde, A., Pontén, F., Johansson, B. R., & Carlsson, P. (2015). Foxf2 is required for brain pericyte differentiation and development and maintenance of the blood-brain barrier. Developmental Cell, 34(1), 19–32. https://doi.org/10.1016/j.devcel.2015.05.008.
Ribeiro, A. L., & Okamoto, O. K. (2015). Combined effects of pericytes in the tumor microenvironment. Stem Cells International, 2015, 8. https://doi.org/10.1155/2015/868475.
Ricci-Vitiani, L., Pallini, R., Biffoni, M., Todaro, M., Invernici, G., Cenci, T., et al. (2010). Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature, 468(7325), 824–828. https://doi.org/10.1038/nature09557.
Roh, T. H., Park, H. H., Kang, S.-G., Moon, J. H., Kim, E. H., Hong, C.-K., et al. (2017). Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis. Medicine, 96(27), e7422. https://doi.org/10.1097/md.0000000000007422.
Rolle, C. E., Sengupta, S., & Lesniak, M. S. (2010). Challenges in clinical design of immunotherapy trials for malignant glioma. Neurosurgery Clinics of North America, 21(1), 201–214. https://doi.org/10.1016/j.nec.2009.08.002.
Rong, Y., Durden, D. L., Van Meir, E. G., & Brat, D. J. (2006). ‘Pseudopalisading’ necrosis in glioblastoma: A familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. Journal of Neuropathology & Experimental Neurology, 65(6), 529.
Rosenberg, S. A., & Restifo, N. P. (2015). Adoptive cell transfer as personalized immunotherapy for human cancer. Science, 348(6230), 62–68. https://doi.org/10.1126/science.aaa4967.
Rostomily, R. C., Spence, A. M., & Silbergeld, D. L. (2005). Neurosurgical management of high-grade gliomas. In A. J. Moore & D. W. Newell (Eds.), Neurosurgery: Principles and practice (pp. 167–186). London: Springer London.
Safa, A. R., Saadatzadeh, M. R., Cohen-Gadol, A. A., Pollok, K. E., & Bijangi-Vishehsaraei, K. (2015). Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs. Genes & Diseases, 2(2), 152–163. https://doi.org/10.1016/j.gendis.2015.02.001.
Sattiraju, A., Sai, K. K. S., & Mintz, A. (2017a). Glioblastoma stem cells and their microenvironment. Advances in Experimental Medicine and Biology, 1041, 119–140. https://doi.org/10.1007/978-3-319-69194-7_7.
Sattiraju, A., Sun, Y., Solingapuram Sai, K. K., Li, K. C. P., & Mintz, A. (2017b). Maximizing local access to therapeutic deliveries in glioblastoma. Part IV: Image-guided, remote-controlled opening of the blood-brain barrier for systemic brain tumor therapy. In S. De Vleeschouwer (Ed.), Glioblastoma. Brisbane (AU): Codon Publications. Copyright: The Authors.
Sattiraju, A., Xiong, X., Pandya, D. N., Wadas, T. J., Xuan, A., Sun, Y., et al. (2017c). Alpha particle enhanced blood brain/tumor barrier permeabilization in glioblastomas using integrin alpha-v beta-3-targeted liposomes. Molecular Cancer Therapeutics, 16(10), 2191–2200. https://doi.org/10.1158/1535-7163.mct-16-0907.
Scott, M. A., Shen, J., Lam, K., Yen, Y. H., Shrestha, S., Mravic, M., Asatrian, G., Chung, C. G., Lugassy, C., Barnhill, R. L., Dry, S. M., Peault, B., & James, A. W. (2015). Review of pericytes in tumor biology. International Journal of Orthopaedics, 2(3), 301–306.
Segerman, A., Niklasson, M., Haglund, C., Bergström, T., Jarvius, M., Xie, Y., et al. (2016). Clonal variation in drug and radiation response among glioma-initiating cells is linked to proneural-mesenchymal transition. Cell Reports, 17(11), 2994–3009. https://doi.org/10.1016/j.celrep.2016.11.056.
Sharpe, A. H., & Abbas, A. K. (2006). T-cell costimulation—biology, therapeutic potential, and challenges. New England Journal of Medicine, 355(10), 973–975. https://doi.org/10.1056/NEJMp068087.
Singh, S. K., Clarke, I. D., Hide, T., & Dirks, P. B. (2004a). Cancer stem cells in nervous system tumors. Oncogene, 23(43), 7267–7273. https://doi.org/10.1038/sj.onc.1207946.
Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., et al. (2004b). Identification of human brain tumour initiating cells. Nature, 432, 396–401. https://doi.org/10.1038/nature03128.
Soda, Y., Marumoto, T., Friedmann-Morvinski, D., Soda, M., Liu, F., Michiue, H., et al. (2011). Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 108(11), 4274–4280. https://doi.org/10.1073/pnas.1016030108.
Song, K. S., Phi, J. H., Cho, B.-K., Wang, K.-C., Lee, J. Y., Kim, D. G., et al. (2010). Long-term outcomes in children with glioblastoma. Journal of Neurosurgery: Pediatrics, 6(2), 145–149. https://doi.org/10.3171/2010.5.PEDS09558.
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J. B., Janzer, R. C., et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The Lancet Oncology, 10(5), 459–466. https://doi.org/10.1016/S1470-2045(09)70025-7.
Suri, C., Jones, P. F., Patan, S., Bartunkova, S., Maisonpierre, P. C., Davis, S., et al. (1996). Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell, 87(7), 1171–1180.
Svensson, A., Özen, I., Genové, G., Paul, G., & Bengzon, J. (2015). Endogenous brain pericytes are widely activated and contribute to mouse glioma microvasculature. PLoS One, 10(4), e0123553. https://doi.org/10.1371/journal.pone.0123553.
Sweeney, M. D., Ayyadurai, S., & Zlokovic, B. V. (2016). Pericytes of the neurovascular unit: Key functions and signaling pathways. Nature Neuroscience, 19, 771. https://doi.org/10.1038/nn.4288. https://www.nature.com/articles/nn.4288#supplementary-information.
Valdor, R., Garcia-Bernal, D., Bueno, C., Rodenas, M., Moraleda, J. M., Macian, F., & Martinez, S. (2017). Glioblastoma progression is assisted by induction of immunosuppressive function of pericytes through interaction with tumor cells. Oncotarget, 8(40), 68614–68626. https://doi.org/10.18632/oncotarget.19804.
Van Meir, E. G., Hadjipanayis, C. G., Norden, A. D., Shu, H. K., Wen, P. Y., & Olson, J. J. (2010). Exciting new advances in neuro-oncology: The avenue to a cure for malignant glioma. CA: A Cancer Journal for Clinicians, 60(3), 166–193. https://doi.org/10.3322/caac.20069.
Wang, M., Yin, B., Wang, H. Y., & Wang, R. F. (2014). Current advances in T-cell-based cancer immunotherapy. Immunotherapy, 6(12), 1265–1278. https://doi.org/10.2217/imt.14.86.
Watkins, S., Robel, S., Kimbrough, I. F., Robert, S. M., Ellis-Davies, G., & Sontheimer, H. (2014). Disruption of astrocyte-vascular coupling and the blood-brain barrier by invading glioma cells. Nature Communications, 5, 4196–4196. https://doi.org/10.1038/ncomms5196.
Weller, M., Cloughesy, T., Perry, J. R., & Wick, W. (2012). Standards of care for treatment of recurrent glioblastoma—Are we there yet? Neuro-Oncology, 15, 4–27. https://doi.org/10.1093/neuonc/nos273.
Wolburg, H., & Lippoldt, A. (2002). Tight junctions of the blood–brain barrier: Development, composition and regulation. Vascular Pharmacology, 38(6), 323–337. https://doi.org/10.1016/S1537-1891(02)00200-8.
Wolburg, H., Noell, S., Fallier-Becker, P., Mack, A. F., & Wolburg-Buchholz, K. (2012). The disturbed blood-brain barrier in human glioblastoma. Molecular Aspects of Medicine, 33(5-6), 579–589. https://doi.org/10.1016/j.mam.2012.02.003.
Xian, X., Håkansson, J., Ståhlberg, A., Lindblom, P., Betsholtz, C., Gerhardt, H., & Semb, H. (2006). Pericytes limit tumor cell metastasis. The Journal of Clinical Investigation, 116(3), 642–651. https://doi.org/10.1172/JCI25705.
Xiong, X., Sun, Y., Sattiraju, A., Jung, Y., Mintz, A., Hayasaka, S., & Li, K. C. P. (2015). Remote spatiotemporally controlled and biologically selective permeabilization of blood-brain barrier. Journal of Controlled Release: Official Journal of the Controlled Release Society, 217, 113–120. https://doi.org/10.1016/j.jconrel.2015.08.044.
Yang, Y. (2015). Cancer immunotherapy: Harnessing the immune system to battle cancer. The Journal of Clinical Investigation, 125(9), 3335–3337. https://doi.org/10.1172/jci83871.
Zhang, L., Wang, Y., Rashid, M. H., Liu, M., Angara, K., Mivechi, N. F., et al. (2017). Malignant pericytes expressing GT198 give rise to tumor cells through angiogenesis. Oncotarget, 8(31), 51591–51607. https://doi.org/10.18632/oncotarget.18196.
Zong, H., Verhaak, R. G. W., & Canoll, P. (2012). The cellular origin for malignant glioma and prospects for clinical advancements. Expert Review of Molecular Diagnostics, 12(4), 383–394. https://doi.org/10.1586/erm.12.30.
Lidar, Z., Mardor, Y., Jonas, T., Pfeffer, R., Faibel, M., Nass, D., et al. (2004). Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: A phase I/II clinical study. Journal of Neurosurgery, 100(3), 472–479. https://doi.org/10.3171/jns.2004.100.3.0472.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Sattiraju, A., Mintz, A. (2019). Pericytes in Glioblastomas: Multifaceted Role Within Tumor Microenvironments and Potential for Therapeutic Interventions. In: Birbrair, A. (eds) Pericyte Biology in Disease. Advances in Experimental Medicine and Biology, vol 1147. Springer, Cham. https://doi.org/10.1007/978-3-030-16908-4_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-16908-4_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-16907-7
Online ISBN: 978-3-030-16908-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)